Keywords: TINs; tumor-infiltrating neutrophils; TILs; tumor-infiltrating lymphocytes; NLR; neutrophil/lymphocyte rate; BC; bladder cancer; IHC; immunohistochemistry; OS; overall survival; NMIBC; non-muscle invasive bladder cancer; MIBC; muscle invasive bladder canc
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: urinary bladder neoplasms; neoplasm invasiveness; neoplasm recurrence; local; BCG vaccine; mortality; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; CR; complete response; DSS; disease specific survival; MIBC; muscle invasive bladder cancer; NMIB
Keywords: urinary bladder neoplasms; carcinoma; programmed cell death 1 receptor; immunotherapy; APC; antigen-presenting cell; BCG; bacillus Calmette-Guérin; CD; cluster of differentiation; CR; complete response; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4
Keywords: CIS; carcinoma in situ; MIBC; muscle-invasive bladder cancer; NMIBC; non-muscle-invasive bladder cancer; RC; radical cystectomy; TURBT; transurethral resection of bladder tumour; Bladder cancer; TURBT; T1G3;
Keywords: NMIBC; non-muscle-invasive bladder cancer; PK; plasma kinetic; PKEBT; PK enucleation of bladder tumour; (b)(m)TURBT; (bipolar) (monopolar) transurethral resection of bladder tumour; NMIBC, non-invasive muscle bladder cancer; PKEBT, plasma kinetic enucleat
Keywords: CPEX; cardio-pulmonary exercise testing; LOS; length of stay; MIBC; muscle-invasive bladder cancer; NMIBC; non-muscle invasive disease; RC; radical cystectomy; Bladder cancer; Elderly; Cystectomy; Minimally invasive; Laparoscopy;
Keywords: AJCC; American Joint Committee on Cancer; AUA; American Urological Association; CTU; Computed tomography urography; DWI; diffusion-weighted imaging; MIBC; muscle invasive bladder cancer; NCCN; National Comprehensive Cancer Network; NMIBC; non-muscle invas
Keywords: urinary bladder neoplasms; cystoscopy; aminolevulinic acid; photochemotherapy; drug-related side effects and adverse reactions; AE; adverse event; BLC; blue light cystoscopy; CIS; carcinoma in situ; CTCAE; Common Terminology Criteria for Adverse Events; F
Keywords: BCG vaccine; cancer vaccines; cell cycle checkpoints; immunotherapy; urologic neoplasms; AE; adverse event; APC; antigen presenting cell; BCG; bacillus Calmette-Guérin; CAR; chimeric antigen receptor; CIS; carcinoma in situ; CTA; cancer testis antigen; C
Keywords: urinary bladder neoplasms; administration; intravesical; BCG vaccine; mitomycin; interferons; BCG; bacillus Calmette-Guérin; MMC; mitomycin C; NMIBC; nonmuscle invasive bladder cancer; SOE; strength of evidence; TURBT; transurethral bladder tumor resecti
Keywords: fluorescence; cystoscopy; aminolevulinic acid; urinary bladder neoplasms; 5-ALA; 5-aminolevulinic acid; HAL; hexaminolevulinic acid; NMIBC; nonmuscle invasive bladder cancer; RCT; randomized, controlled trial; SOE; strength of evidence; TURBT; transurethr
Keywords: bladder neoplasms; risk assessment; practice guidelines as topic; mortality; BCG vaccine; BCG; bacillus Calmette-Guérin; CUETO; Club Urológico Español de Tratamiento Oncológico; EORTC; European Organization for Research and Treatment of Cancer; NCCN®
Keywords: urinary bladder neoplasms; drug therapy; neoplasm recurrence; local; guideline adherence; practice patterns; physicians'; IPIOC; immediate postoperative instillation of chemotherapy; NMIBC; nonmuscle invasive bladder cancer; TUR; transurethral resection
Keywords: urinary bladder neoplasms; cystectomy; neoplasm recurrence; local; patient selection; morbidity; BCa; bladder cancer; BCG; bacillus Calmette-Guérin; CG; Clavien grade; CIS; carcinoma in situ; DSS; disease specific survival; LVI; lymphovascular invasion;
Keywords: Biomarker; Cell-free DNA; Circulating DNA; Droplet digital PCR; Genomic variant; Next-generation sequencing; NMIBC; Personalised analysis; Plasma; Urine;
Keywords: incidence; urinary bladder neoplasms; neoplasm staging; Spain; BC; bladder cancer; BCG; bacillus Calmette-Guérin; BMI; body mass index; CIS; carcinoma in situ; MMC; mitomycin C; NMIBC; nonmuscle invasive bladder cancer; TURBT; transurethral bladder tumor
Keywords: urinary bladder; carcinoma; papillary; evidence-based practice; practice guideline; risk; AUA; American Urological Association; CIS; carcinoma in situ; CTU; computerized tomography urogram; EAU; European Association of Urology; ICUD; International Consult
Keywords: urinary bladder; carcinoma; urothelium; gene expression; biological markers; CIS; carcinoma in situ; Cq; cycle quantification; HG; high grade; LG; low grade; LOOCV; leave-one-out cross validation; MIBC; muscle invasive bladder cancer; NMIBC; nonMIBC; PCR;
Keywords: urinary bladder neoplasms; mycobacterium bovis; administration; intravesical; chemotherapy; adjuvant; risk; AUA; American Urological Association; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; CUETO; Club Urologico Espanol de Tratamiento Oncologi
The Role of Vitamin D Receptor Polymorphisms in Predicting the Response to Therapy for Nonmuscle Invasive Bladder Carcinoma
Keywords: urinary bladder neoplasms; carcinoma; polymorphism; single nucleotide; receptors; calcitriol; BCG vaccine; 1,25-VD; activated vitamin D; BCG; bacillus Calmette-Guérin; NMIBC; nonmuscle invasive bladder cancer; PCR; polymerase chain reaction; SNP; single
The challenges of Bacillus of Calmette-Guerin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patients
Keywords: BC; bladder cancer; NMIBC; non muscle invasive bladder cancer; MIBC; muscle invasive bladder cancer; EAU; European association of urology; EORTC; European Organisation for Research and Treatment of Cancer.; TUR; trans-urethral resection; BCG; Bacillus of
Increased expression of GGN promotes tumorigenesis in bladder cancer and is correlated with poor prognosis
Keywords: GGN; gametogenetin; QRT-PCR; quantitative real-time PCR; BrdU; bromodeoxyuridine; MIBC; muscle-invasive bladder cancer; NMIBC; non-muscle-invasive bladder cancer; CRISP2; cysteine-rich secretory protein 2; FANCL; Fanconi anemia complementation group L; FA
Predicting the tumorigenic phenotype of human bladder cancer cells by combining with fetal rat mesenchyme
Keywords: Invasive bladder cancer; Responsiveness of cancer cells to stroma; Fetal mesenchyme; Micropapillary-like structures; p63 isoforms; BLM; bladder mesenchyme; CIS; carcinoma in situ; EMT; epithelial-mesenchymal transition; H&E; hematoxylin and eosin; MIBC; m
Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer
Keywords: BC; bladder cancer; BCG; Bacillus Calmette-Guerin; bFGF; basic fibroblast growth factor; BSA; bovine serum albumin; EGF; epidermal growth factor; GFs; growth factors; HGF; hepatocyte growth factor; HRP; horseradish peroxidase; IFN-γ; interferon-gamma; IG
Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis
Keywords: miRNAs; Urologic cancer; Prognosis; Biomarker; Bioinformatics analysis; miRNA panel; RNA; ribonucleic acid; miRNA; microRNA; KCa; kidney cancer; BCa; bladder cancer; PCa; prostate cancer; TCGA; The Cancer Genome Atlas; OS; overall survival; PSA; prostate
Exploring Patterns of Mitomycin C Use in Community Practice Urology
Keywords: urinary bladder neoplasms; endoscopy; mitomycin; community health services; quality improvement; CCI; Charlson comorbidity index; MMC; mitomycin C; NMIBC; nonmuscle invasive bladder cancer; TURBT; transurethral bladder tumor resection;
Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project
Keywords: urinary bladder neoplasms; neoplasm invasiveness; watchful waiting; risk; cost-benefit analysis; AS; active surveillance; IOF; in-office fulguration; LG; low grade; MIBC; muscle invasive bladder cancer; NMIBC; nonMIBC; TUR; transurethral resection; TURBT;
Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer
Keywords: urinary bladder neoplasms; BCG vaccine; adjuvants; immunologic; skin tests; adverse effects; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; LUTS; lower urinary tract symptoms; NMIBC; nonmuscle invasive bladder cancer; PFS; progression-free surviv
High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma
Keywords: CDKN2A; mRNA; NMIBC; p16; Prognosis;
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Keywords: urinary bladder neoplasms; radiotherapy; cystectomy; drug therapy; AC; adjuvant chemotherapy; AHRQ; Agency for Healthcare Research and Quality; ASCO; American Society of Clinical Oncology; ASTRO; American Society for Radiation Oncology; AUA; American Uro
Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer
Keywords: AKT; AKT serine/threonine kinase 1; BCG; bacillus Calmette-Guérin; CTLA4; cytotoxic T-lymphocyte-associated protein 4; EGFR; epidermal growth factor receptor; FDA; Food and Drug Administration; FGFR; fibroblast growth factor receptor; GC; gemcitabine p
The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer
Keywords: CELLection; CellSearch; NMIBC; Prognosis; TURB;
Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor
Keywords: bladder neoplasms; neoplasm recurrence; local; androgen antagonists; prevention and control; 5-alpha reductase inhibitors; ADT; androgen deprivation therapy; AR; androgen receptor; AST; androgen suppression therapy; BCG; bacillus Calmette-Guérin; BPH; be
Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers
Keywords: BlCa; bladder cancer; BTA; bladder tumor antigen; circRNAs; circular RNA; FDA; United States of America's Food and Drug Administration; FDP; fibrin degradation product; FISH; fluorescent in situ hybridization; GAS-5; growth arrest-specific 5; GHET 1; gast
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study
Keywords: urinary bladder neoplasms; neoplasm recurrence; local; urinalysis; cystoscopy; neoplasm invasiveness; CIS; carcinoma in situ; EAU; European Association of Urology; HG; high grade; LG; low grade; MIBC; muscle invasive bladder cancer; NMIBC; nonmuscle inva
Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis
Keywords: urinary bladder neoplasms; BCG vaccine; immunotherapy; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; FDA; United States Food and Drug Administration; MeSH; Medical Subject Headings; NMIBC; nonmuscle invasive bladder cancer; PRISMA; Preferred Rep
Instillations endovésicales dans les tumeurs de vessie n'infiltrant pas le muscle (TVNIM). Perspectives d'utilisation de la thermochimiothérapie
Keywords: Tumeurs de la vessie; TVNIM; Hyperthermie; Chimiothérapie endo-vésicale; MMC thermochimiothérapie; Bladder cancer; NMIBC; Hyperthermia; Intravesical chemotherapy; Mitomycin-C; Thermochemotherapy;
Therapeutic Use of Mitomycin C for Urological Conditions: Systematic Review of the Literature
Keywords: urethra; urinary bladder neoplasms; mitomycin; anticarcinogenic agents; urological agents; BCG; bacillus Calmette-Guérin; BNC; bladder neck contracture; MMC; mitomycin C; NMIBC; nonmuscle invasive bladder cancer;
The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis
Keywords: urinary bladder neoplasms; BCG vaccine; treatment failure; cystectomy; mortality; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; CSS; cancer specific survival; HG; high grade; IFN; interferon; IVT; intravesical therapy; LVI; lymphovascular invasi
Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes
Keywords: urinary bladder neoplasms; Mycobacterium bovis; mitomycin; drug delivery systems; treatment outcome; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; EMDA; electromotive drug administration; HR; high risk; MIBC; muscle invasive bladder cancer; MMC;
Transurethral Bladder Tumor Resection Can Cause Seeding of Cancer Cells into the Bloodstream
Keywords: urinary bladder neoplasms; neoplastic cells; circulating; neoplasm metastasis; CTC; circulating tumor cell; CV; central vein; IVC; inferior vena cava; MIBC; muscle invasive bladder cancer; NMIBC; nonmuscle invasive bladder cancer; PV; peripheral vein; TUR
Low-dose bacille Calmette–Guérin for non-muscle-invasive bladder cancer: Results of a prospective study
Keywords: BC, bladder cancer; CIS, carcinoma in situ; NMI, non-muscle-invasive; SWOG, Southwest Oncology Group; TURB, transurethral resection of the bladderBCG; Bladder cancer; Low-dose regimen; NMIBC; TURB
Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma
Keywords: TCC; transitional cell carcinoma; BC; bladder cancer; BCG; Bacillus Calmette-Guerin; BPH; Benign prostatic hyperplasia; NMIBC; non-muscle-invasive bladder cancer; MIBC; muscle-invasive bladder cancer; RC; radical cystectomy; CTA; cancer testis antigen; CT
Original StudyDevelopment of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-Guérin Instillations for Bladder Cancer
Keywords: BCG; IL-2; IL-6; NMIBC; Recurrence; Response;
Process Improvements Positively Impact the Use of Intravesical Mitomycin C after Transurethral Resection of Nonmuscle Invasive Bladder Cancer in a Large, Urban Urology Practice
Keywords: mitomycin; urinary bladder neoplasms; MMC; mitomycin C; NMIBC; nonmuscle invasive bladder cancer; TURB; transurethral resection of the bladder;
TaG1 Bladder Cancer: A Third of All Primary Tumors and 80% of All Recurrences Can Be Treated in the Office Using Local Anesthesia
Keywords: urinary bladder neoplasms; neoplasm recurrence; local; cystoscopy; anesthesia; physicians' offices; GA; general anesthesia; LA; local anesthesia; NMIBC; nonmuscle invasive bladder cancer; OR; operating room; TUR; transurethral resection;
Epigenetic Inactivation of KLF4 is Associated with Urothelial Cancer Progression and Early Recurrence
Keywords: urinary bladder; urothelium; carcinoma; genes; tumor suppressor; mortality; 5-AZA-dc; 5-aza-2-deoxycytidine; EMT; epithelial-to-mesenchymal transition; GAPDH; glyceraldehyde-3-phosphate dehydrogenase; KLF4; Krüppel-like factor 4; NMIBC; nonmuscle invasiv
Upper Tract Imaging Surveillance is not Effective in Diagnosing Upper Tract Recurrence in Patients Followed for Nonmuscle Invasive Bladder Cancer
Keywords: carcinoma; transitional cell; urinary bladder neoplasms; diagnostic imaging; watchful waiting; CIS; carcinoma in situ; CT; computerized tomography; IVP; excretory urography; MSKCC; Memorial Sloan-Kettering Cancer Center; NMIBC; nonmuscle invasive bladder
Disease Specific Mortality in Patients with Low Risk Bladder Cancer and the Impact of Cystoscopic Surveillance
Keywords: urinary bladder; urinary bladder neoplasms; risk; cystoscopy; Great Britain; BC; bladder cancer; DSM; disease specific mortality; MIBC; muscle invasive BC; NHS; National Health Service; NMI; nonmuscle invasive; NMIBC; nonmuscle invasive bladder cancer; UC
Comment suivre un schéma d'instillation du BCG en toute sécurité en 2013Â ?
Keywords: TVNIM; BCG thérapie; Complications; NMIBC; BCG bladder instillation; Complications;